We are live on ! Find out more

HELP

Helus Pharma Inc. Common Stock

HELP

Market cap $613M

8.39 USD

-0.29

3.34%

At close Updated Nov 5, 4:00 PM EST

Pre-market

After hours

8.38

-0.01

0.12%

1 day

-3.34%

5 days

-20.32%

1 month

-26.53%

3 months

-20.32%

6 months

60.73%

Year to date

1.33%

1 year

41.01%

5 years

-90.44%

10 years

-92%

About: Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Employees: 50

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.4%

Neutral 84.6%

Negative 0%

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development

Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that co-founders Eric So and Paul Glavine have stepped down from their respective executive and consulting roles while continuing to serve as members of Helus Pharma's Board of Directors.

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Cybin NASDAQ: HELP outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026.

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Zacks Investment Research

Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma to Host Investor Presentation on October 21, 2026

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.

Helus Pharma to Host Investor Presentation on October 21, 2026

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company's annual and special meeting of shareholders held on September 22, 2026.

Helus Pharma Announces Completion of Legal Name Change

See News Rankings

Price charts implemented using Lightweight Charts™